Gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, is the fourth leading cause of cancer-related death worldwide, with the highest incidence rates occurring in Eastern Asia and Eastern Europe.1 It's challenging to diagnose and treat as the majority of patients with gastric cancer don't present symptoms in early stages.2 In fact, more than 80% of patients with gastric cancer in the U.S. are diagnosed at an advanced stage and face a poor prognosis and low [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Permalink

Disclaimer

Amgen Inc. published this content on 16 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 April 2024 20:03:23 UTC.